These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 3145882)

  • 1. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperaminoacidemia in epileptic children treated with valproic acid.
    Castro-Gago M; Rodrigo-Saez E; Novo-Rodriguez I; Camiña MF; Rodriguez-Segade S
    Childs Nerv Syst; 1990 Dec; 6(8):434-6. PubMed ID: 2095300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S; Mitsudome A; Yasumoto S; Ogawa A; Muta Y; Tomoda Y
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.
    Zaccara G; Campostrini R; Paganini M; Moroni F; Valenza T; Targioni G; Arnetoli G; Zappoli R; Baruzzi A
    Neurology; 1984 Nov; 34(11):1519-21. PubMed ID: 6436733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients.
    Garzón P; González-Cornejo S; Román-Maldonado S; Navarro-Ruiz A
    Gen Pharmacol; 1985; 16(4):411-3. PubMed ID: 2412936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
    Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A
    Seizure; 2018 May; 58():90-95. PubMed ID: 29679911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents.
    Steinborn B; Galas-Zgorzalewicz B
    Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and total serum valproate concentrations: their relationship to seizure control, liver enzymes and plasma ammonia in children.
    Farrell K; Abbott FS; Orr JM; Applegarth DA; Jan JE; Wong PK
    Can J Neurol Sci; 1986 Aug; 13(3):252-5. PubMed ID: 3091231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum copper and zinc levels in epileptic children with valproate treatment.
    Kaji M; Ito M; Okuno T; Momoi T; Sasaki H; Yamanaka C; Yorifuji T; Mikawa H
    Epilepsia; 1992; 33(3):555-7. PubMed ID: 1592036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid free fraction in epileptic children under chronic monotherapy.
    Riva R; Albani F; Franzoni E; Perucca E; Santucci M; Baruzzi A
    Ther Drug Monit; 1983 Jun; 5(2):197-200. PubMed ID: 6410546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.